Myasthenia Gravis
Conditions
Interventions
Treated with novel biologics:None
Sponsors
The First Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 95 Years
Inclusion criteria
Inclusion criteria: 1) Patients with MG = 18 years of age; 2) MGFA Class II-IV; 3) QMG score =6; 4) Not treated or receiving a stable dose of MG treatments.
Exclusion criteria
Exclusion criteria: 1) Have been treated with novel biologics (including rituximab, olfatumumab, eculizumab, efgartigimod, etc.) in the pase 6 months. 2) Had a thymectomy inthe past 3 months. 3) Have been treated with IVIg/plasma exchange in the past month. 4) Suffering from active hepatitis B, or hepatitis C antibody positive, or HIV antibody positive and low CD4 count. 5) Female patients who are pregnant. 6) Suffering from other serious chronic diseases that may affect the evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| QMG; | — |
Secondary
| Measure | Time frame |
|---|---|
| MG-ADL;IgG;Cytokine;Deterioration & recurrence rate;Myasthenia gravis related antibodies; | — |
Countries
China
Contacts
Public ContactXiuming Guo
The First Affiliated Hospital of Chongqing Medical University
Outcome results
None listed